Vascular Biology |
From the First Department of Internal Medicine (M.O., S.Y., M.Y., J.N., H.T.), Yamagata University School of Medicine, and the Institute for Life Support Technology (S.F., T.Y.), Yamagata Technopolis Foundation, Yamagata, Japan.
Correspondence to Seiji Yamaguchi, MD, First Department of Internal Medicine, Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan. E-mail syamaguc{at}med id. yamagata-u.ac.jp
AbstractThe biological actions
of tumor necrosis factor-
(TNF-
) are mediated by 2 distinct
receptors, TNF-RI (p55) and TNF-RII (p75). The extracellular domains of
both receptors are shed in soluble form (sTNF-RI and sTNF-RII). The
soluble receptors are involved in regulating TNF-
activities and may
have therapeutic potential as TNF-neutralizing agents. However, it
remains unclear as to what kind of physiological
molecule can regulate TNF receptors. Nitric oxide (NO) mediates a
variety of biological and pathophysiological
functions. We hypothesized that NO may modulate the expression and
shedding of TNF-RI. An NO donor, diethylamine/NO complex (NOC 5),
increased sTNF-RI in the supernatants of ECV304, a human umbilical vein
cell line, in a dose-dependent manner. TNF-RI mRNA in these cells was
upregulated by NOC 5. 8-Br-cGMP and peroxynitrate had no effect
on sTNF-RI release. Genistein and herbimycin A, inhibitors
of tyrosine kinase, inhibited sTNF-RI release. Herbimycin A inhibited
the levels of TNF-RI mRNA enhanced by NOC 5, which downregulated the
surface expression of TNF-RI, indicating that NO is also involved in
the shedding process of TNF-RI. The shedding of TNF-RI was abolished by
a synthetic inhibitor of matrix metalloproteinase,
KB-R8301. In conclusion, NO enhanced the release of sTNF-RI from
endothelial cells by a cGMP-independent mechanism. Dual
pathways suggested for NO-induced sTNF-RI release include (1) enhanced
expression of TNF-RI, at least partially, by a tyrosine
kinasedependent mechanism and (2) increased shedding of TNF-RI by a
type of metalloproteinase.
Key Words: nitric oxide TNF-
TNF receptor (p55) human endothelial cells tyrosine kinase inhibitor
This article has been cited by other articles:
![]() |
J. J. Boyle, P. L. Weissberg, and M. R. Bennett Tumor Necrosis Factor-{alpha} Promotes Macrophage-Induced Vascular Smooth Muscle Cell Apoptosis by Direct and Autocrine Mechanisms Arterioscler Thromb Vasc Biol, September 1, 2003; 23(9): 1553 - 1558. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. M. Dias, A. R. Goodman, J. L. Dos Santos, R. N. Gomes, A. Altmeyer, P. T. Bozza, M. de Fatima Horta, J. Vilcek, and L. F. L. Reis TSG-14 transgenic mice have improved survival to endotoxemia and to CLP-induced sepsis J. Leukoc. Biol., June 1, 2001; 69(6): 928 - 936. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-M. Fernandez-Real, B. Lainez, J. Vendrell, M. Rigla, A. Castro, G. Penarroja, M. Broch, A. Perez, C. Richart, P. Engel, et al. Shedding of TNF-alpha receptors, blood pressure, and insulin sensitivity in type 2 diabetes mellitus Am J Physiol Endocrinol Metab, April 1, 2002; 282(4): E952 - E959. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |